Oculis Stock Forecast
NASDAQ: OCSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:24 PM ET
OCS analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$36.49+321.12%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Oculis (2026-10-08), 10 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $36.49, with a high estimate of $43.64 and a low estimate of $19.51. The average target implies upside of 321.1% from the current price of $8.67.
The spread between the highest and lowest targets is 123.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for OCS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 30% |
| Buy | 7 | 70% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $19.51 | +125.16% |
| Average target | $36.49 | +321.12% |
| High target | $43.64 | +403.64% |